← Back to headlines
Incyte Nears $2 Billion Deal for Star Therapeutics
Incyte is reportedly nearing a deal worth up to $2 billion to acquire Star Therapeutics, a developer of drugs for blood disorders. This acquisition would significantly expand Incyte's portfolio in the blood disorder treatment market.
7 Jun, 10:00 — 7 Jun, 12:51
The Story
Analyzing sources…
Source Diversity
Source Diversity
Moderate (32/100)2 sources— more sources would strengthen this score15/33
Spectrum spread— 2/5 buckets covered8/33
Far L
Left
Center1
Center (1)
FT
Right1
Right (1)
seeking-alpha
Far R
Geographic diversity— 2 regions9/34
US1UK1
ℹOnly 2 sources cover this story
Sources
Showing 2 of 2 sources
FTVery High5h ago
Incyte nears up to $2bn deal for blood disorder biotech Star
Midsized drug manufacturers are supplementing pipelines and scaling up in competition with Big Pharma
Read full article →seeking-alphaMixed2h ago
Incyte nears $2B deal for blood disorder drug developer Star Therapeutics: FT
Read full article →Coverage Timeline
First report: FT · 7 Jun, 10:00|Full coverage: 2 · 3h|Window: 3h
Left-leaningCenterRight-leaning
